Fig. 3: OncoTarget/OncoTreat-predicted drugs targeting MRs co-segregate with OPC, OC and AC cell states. | Nature Genetics

Fig. 3: OncoTarget/OncoTreat-predicted drugs targeting MRs co-segregate with OPC, OC and AC cell states.

From: Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states

Fig. 3: OncoTarget/OncoTreat-predicted drugs targeting MRs co-segregate with OPC, OC and AC cell states.The alternative text for this image may have been generated using AI.

a, Heatmaps showing the statistical significance of OncoTarget-predicted drug targets (left; rows) and OncoTreat-predicted MR-inverter drugs (right; rows) across the seven DMG cell states (columns) quantified as −log10(Bonferroni-adjusted P values) derived from the respective one-sided aREA, displayed both as a maroon color scale and numerically within each heatmap cell. Analyses were performed using cell-state-specific, Stouffer-integrated synthetic bulk VIPER-inferred tumorigenic protein activity profiles (GTEx caudate reference). The OncoTarget Top and OncoTreat Top heatmaps display the top 20 drug targets and MR-inverter drugs (that is, drugs predicted to invert the activity of the top 50 most aberrantly active tumorigenic MRs), respectively, for each cell state. The OncoTarget Unique heatmap highlights significantly activated drug targets uniquely associated with individual cell states. b, Schematic illustrating the known MoA of five drugs selected to target OPC-like states (purple) and four drugs selected to target AC-like states (pink) for in vivo validation. Figure adapted from previous publications83,84 and created in BioRender; Calvo Fernandez, E. https://BioRender.com/ud8gakw (2025).

Back to article page